Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 29 points (-0.2%) at 16,877 as of Thursday, June 19, 2014, 1:00 PM ET. The NYSE advances/declines ratio sits at 1,663 issues advancing vs. 1,297 declining with 187 unchanged. The Health Care sector currently sits down 0.3% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the sector include Regeneron Pharmaceuticals ( REGN), down 2.0%, Shire ( SHPG), down 1.6%, Vertex Pharmaceuticals ( VRTX), down 1.2%, Valeant Pharmaceuticals International ( VRX), down 1.2% and Actavis ( ACT), down 0.9%. Top gainers within the sector include Medtronic ( MDT), up 1.5%, WellPoint ( WLP), up 1.1%, UnitedHealth Group ( UNH), up 1.0%, Humana ( HUM), up 0.9% and Sanofi ( SNY), up 1.1%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Alexion Pharmaceuticals ( ALXN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Alexion Pharmaceuticals is down $2.01 (-1.2%) to $158.42 on light volume. Thus far, 463,572 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $157.84-$160.92 after having opened the day at $160.91 as compared to the previous trading day's close of $160.43. Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $31.7 billion and is part of the drugs industry. Shares are up 20.5% year-to-date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, increase in net income and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexion Pharmaceuticals Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.